Here's Why This Biotechnology Skyrocketed by 439% in December [Yahoo! Finance]
Capricor Therapeutics, Inc. (CAPR)
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
capricor.com/investors
Company Research
Source: Yahoo! Finance
10 stocks we like better than Capricor Therapeutics › Capricor Therapeutics (NASDAQ: CAPR) stock rose an incredible 439.4% in December, according to data provided by S&P Global Market Intelligence . The move followed the company's announcement of positive top-line results from a Phase 3 trial of Deramiocel, a cell therapy for the treatment of Duchenne muscular dystrophy (DMD). However, the story is not quite as simple as a Phase 3 trial hitting its primary endpoints, as you will soon see. DMD is a genetic disorder occurring in 1 in 3,500 to 5,000 births. There are about 15,000 sufferers in the U.S. and 200,000 worldwide. Nearly entirely impacting boys, it's a severe disorder that causes a weakening of muscles and atrophy because a genetic mutation prevents the body from producing sufficient dystrophin. That matters because dystrophin is a structural protein that helps strengthen muscle fibers and protect them from damage during contraction. Deramiocel is a cell therapy derived
Show less
Read more
Impact Snapshot
Event Time:
CAPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting Capricor Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CAPR
News
- Capricor Therapeutics (NASDAQ:CAPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.MarketBeat
- Capricor Therapeutics (NASDAQ:CAPR) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=CAPR&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall SMarketBeat
- Capricor Therapeutics: A High Risk/High Reward Name [Seeking Alpha]Seeking Alpha
- Capricor Therapeutics (NASDAQ:CAPR) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=CAPR&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Capricor Therapeutics, Inc. (CAPR): A Bear Case Theory [Yahoo! Finance]Yahoo! Finance
CAPR
Earnings
- 11/10/25 - In-Line
CAPR
Sec Filings
- 1/7/26 - Form 4
- 1/7/26 - Form 4
- 1/7/26 - Form 4
- CAPR's page on the SEC website